



MaxCyte to Participate in Upcoming Investor Conferences

June 1, 2023 8:06 PM EDT

ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate at the following investor conferences:

- William Blair 43rd Annual Growth Stock Conference
Thursday, June 8 at 8:00 a.m. Central Time
- TD Cowen 2nd Annual Tools/Dx Revolution
Monday, June 26th at 3:10 PM Pacific Time

A live and archived webcast of the William Blair Presentation will be available on the "Events" section of the MaxCyte investor relations website at <https://investors.maxcyte.com/>.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on [Twitter](#) and [LinkedIn](#).

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com

US Media Relations

Spectrum Seismic Collaborative

Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com